These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32740371)

  • 41. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.
    Song J; Kang S; Choi SW; Seo KW; Lee S; So MW; Lim DH
    Rheumatol Int; 2020 Jun; 40(6):991-995. PubMed ID: 32314010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
    Ding JG; Li J; Hong L; Yu XQ; Ye EL; Sun GQ; Zhang XX; Chen L; Sun QF
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5788-5796. PubMed ID: 32495917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
    Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
    J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain.
    Goicoechea M; Sánchez Cámara LA; Macías N; Muñoz de Morales A; Rojas ÁG; Bascuñana A; Arroyo D; Vega A; Abad S; Verde E; García Prieto AM; Verdalles Ú; Barbieri D; Delgado AF; Carbayo J; Mijaylova A; Acosta A; Melero R; Tejedor A; Benitez PR; Pérez de José A; Rodriguez Ferrero ML; Anaya F; Rengel M; Barraca D; Luño J; Aragoncillo I
    Kidney Int; 2020 Jul; 98(1):27-34. PubMed ID: 32437770
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
    Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
    Lee JE; Lee SO; Heo J; Kim DW; Park MR; Son H; Kim D; Kim KH; Lee S; Lee SH
    Antivir Ther; 2021; 26(1-2):34-42. PubMed ID: 35485345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.
    Choi MJ; Kang M; Shin SY; Noh JY; Cheong HJ; Kim WJ; Jung J; Song JY
    Int J Infect Dis; 2021 Jan; 102():275-281. PubMed ID: 33127507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study.
    Kim J; Jung J; Kim TH; Kang N; Choi H; Oh DH; Ahn MY; Kim SH; Hahm C; Lee YK; Park K; Hong K; Choi JP
    BMC Infect Dis; 2021 Sep; 21(1):952. PubMed ID: 34521365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
    Huang YQ; Tang SQ; Xu XL; Zeng YM; He XQ; Li Y; Harypursat V; Lu YQ; Wan Y; Zhang L; Sun QZ; Sun NN; Wang GX; Yang ZP; Chen YK
    Front Pharmacol; 2020; 11():1071. PubMed ID: 32765274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ritonavir-boosted lopinavir as maintenance monotherapy in HIV-infected patients who achieved viral suppression during a second-line protease inhibitor-based regimen: a pilot randomized trial (BIDI-MONO).
    Siripassorn K; Chottanapund S; Prasithsirikul W; Manosuthi W
    J Int Assoc Provid AIDS Care; 2014; 13(4):353-60. PubMed ID: 25513033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019.
    Liu JY; Hua MX; Du CJ; Pu L; Xiang P; Li CS; Xiong HF; Liu XZ; Chen ZH; Xie W; Li A
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11939-11944. PubMed ID: 33275267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
    Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F
    Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
    Estella Á; Garnacho-Montero J
    Med Intensiva (Engl Ed); 2020 Nov; 44(8):509-512. PubMed ID: 32423569
    [No Abstract]   [Full Text] [Related]  

  • 58. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment.
    Macías J; Pinilla A; Lao-Dominguez FA; Corma A; Contreras-Macias E; González-Serna A; Gutierrez-Pizarraya A; Fernández-Fuertes M; Morillo-Verdugo R; Trigo M; Real LM; Pineda JA
    Sci Rep; 2020 Dec; 10(1):20958. PubMed ID: 33262433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
    Lopez-Cortes LF; Ruiz-Valderas R; Sánchez-Rivas E; Lluch A; Gutierrez-Valencia A; Torres-Cornejo A; Benmarzouk-Hidalgo OJ; Viciana P
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3746-51. PubMed ID: 23716055
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
    Pulido F; Estrada V; Baril JG; Logue K; Schewe K; Plettenberg A; Duiculescu D; Yau L; Vavro C; Lim ML; Pharo C
    HIV Clin Trials; 2009; 10(2):76-87. PubMed ID: 19487177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.